RC
RCEL.US Avita Medical Ltd
- Market cap
- USD 500M
- P/E
- -
- P/B
- 11.77x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RCEL.US undervalued?
Graham numberThe Graham number of Avita Medical Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Avita Medical Ltd fundamental analysis
No fundamental analysis for Avita Medical Ltd yet.
Avita Medical Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Avita Medical Ltd
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can…
Full company profileAvita Medical Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Avita Medical Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.34M | 1.54M | 1.70M | 5.40M | 5.40M | 33.0M | 34.4M | 50.1M | 64.3M | 71.6M | 89.4M |
| Gross Profit | 805K | 881K | 703K | 4.21M | 4.21M | 26.9M | 28.4M | 42.4M | 55.2M | 58.8M | 73.9M |
| Operating Income | -13.8M | -16.5M | -13.8M | -24.7M | -24.7M | -25.1M | -27.5M | -42.7M | -56.6M | -42.5M | -24.4M |
| EBITDA | -15.1M | -16.4M | -25.3M | -24.7M | -24.7M | -24.1M | -26.0M | -33.5M | -55.3M | -41.2M | -25.1M |
| Net Income | -13.8M | -15.0M | -23.4M | -24.6M | -24.6M | -25.1M | -26.7M | -35.4M | -61.8M | -48.6M | -32.7M |
| EPS | -2.76 | -2.24 | -2.51 | -1.10 | -1.21 | -1.03 | -1.07 | -1.40 | -2.39 | -1.74 | -1.06 |
| Balance Sheet | |||||||||||
| Total Assets | 11.5M | 10.0M | 31.2M | 25.8M | 82.5M | 116M | 98.3M | 112M | 79.7M | 56.4M | 46.8M |
| Total Liabilities | 2.35M | 3.32M | 5.45M | 4.95M | 10.1M | 11.4M | 13.5M | 62.6M | 75.2M | 73.0M | 77.8M |
| Shareholders' Equity | 9.18M | 6.69M | 25.8M | 20.8M | 72.4M | 105M | 84.7M | 49.1M | 4.50M | -16.7M | -31.0M |
| Cash & Short-term Investments | 5.59M | 4.95M | 20.1M | 20.2M | 73.6M | 85.2M | 79.3M | 89.1M | 35.9M | 18.2M | 10.5M |
| Total Debt | 0.00 | 0.00 | 182K | 37.9K | 1.92M | 1.64M | 918K | 42.4M | 46.0M | 46.0M | 47.1M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -7.30M | -8.43M | -13.0M | -27.5M | -22.7M | -18.0M | -19.1M | -38.0M | -48.9M | -31.2M | -19.0M |
| Capital Expenditure | 47.1K | 426K | 365K | 1.51M | 847K | 487K | 525K | 1.45M | 9.33M | 1.74M | 317K |
| Free Cash Flow | -7.35M | -8.85M | -13.3M | -29.0M | -23.6M | -18.5M | -19.6M | -39.5M | -58.3M | -32.9M | -19.4M |
| Ratios | |||||||||||
| ROE | -149.9% | -224.7% | -90.6% | -118.2% | -34.0% | -24.0% | -31.5% | -72.1% | -1,374.6% | - | - |
| ROA | -119.4% | -150.1% | -74.8% | -95.5% | -29.9% | -21.7% | -27.1% | -31.7% | -77.6% | -86.2% | -69.8% |
| Net Profit Margin | -1,025.1% | -975.0% | -1,370.8% | -456.3% | -456.3% | -76.1% | -77.5% | -70.6% | -96.3% | -67.8% | -36.5% |
| Debt to Equity | 0.00x | 0.00x | 0.01x | 0.00x | 0.03x | 0.02x | 0.01x | 0.86x | 10.22x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Avita Medical Ltd dividends
Avita Medical Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 1:5 on Jun 30, 2020.
Who owns Avita Medical Ltd
- Insiders 1.49%
- Institutions 28.98%
- Public & others 69.53%
- Shares outstanding 31.7M
- Free float 31.0M
Top funds holding RCEL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 958K | 3.06% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 143K | 0.46% | -8.38% | Sep 2026 |
| iShares Micro-Cap ETF | 95.0K | 0.30% | 0.00% | Oct 2026 |
| SEI Tax-Managed Small/Mid Cap F (SIMT) | 62.3K | 0.20% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 60.8K | 0.19% | -0.05% | Sep 2026 |
| Fidelity Series Total Market Index | 48.1K | 0.15% | 0.00% | Sep 2026 |
| Goldman Sachs Absolute Ret Trckr Instl | 42.2K | 0.13% | +78.61% | Jun 2026 |
| FullerThaler Behvrl Mcr-Cp Eq Instl | 36.7K | 0.12% | +1.81% | Sep 2026 |
| SEI Small Cap II A (SIIT) | 24.2K | 0.08% | -17.12% | Oct 2026 |
| Gestión Boutique VI Kaldi FI | 22.0K | 0.07% | 0.00% | Oct 2026 |
| Vanguard Balanced Index Inv | 18.8K | 0.06% | 0.00% | Sep 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 15.7K | 0.05% | 0.00% | Sep 2026 |
| Gabelli Health & Wellness | 15.0K | 0.05% | 0.00% | Jun 2026 |
| Schwab Total Stock Market Index | 15.0K | 0.05% | 0.00% | Sep 2026 |
| GS Absolute Ret Trkr I Acc EUR Hdg | 14.4K | 0.05% | 0.00% | Aug 2026 |
| Fidelity Nasdaq Composite Index | 13.9K | 0.04% | -28.65% | Aug 2026 |
| Vanguard U.S. Eq Idx £ Acc | 12.8K | 0.04% | +31.19% | Sep 2026 |
| China Universal Gbl YLBJ QDII CNH | 12.5K | 0.04% | +150.00% | Jun 2026 |
Top institutions holding RCEL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 1.33M | 4.25% | -0.09% | Jun 2026 |
| BlackRock Inc | 565K | 1.80% | -50.14% | Jun 2026 |
| Geode Capital Management, LLC | 340K | 1.08% | -37.41% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 338K | 1.08% | +543.79% | Jun 2026 |
| AQR Capital Management LLC | 321K | 1.02% | +240.20% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 200K | 0.64% | +27.18% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 182K | 0.58% | -5.70% | Jun 2026 |
| Goss Wealth Management LLC | 149K | 0.48% | +71.41% | Jun 2026 |
| Macquarie Group Ltd | 144K | 0.46% | +1,111.26% | Jun 2026 |
| State Street Corp | 129K | 0.41% | -69.94% | Jun 2026 |
| Quantinno Capital Management LP | 105K | 0.34% | +368.12% | Jun 2026 |
| Divisadero Street Capital Management, LP | 100K | 0.32% | 0.00% | Jun 2026 |
| UBS Group AG | 84.0K | 0.27% | +34.55% | Jun 2026 |
| The Goldman Sachs Group Inc | 76.7K | 0.24% | -23.14% | Jun 2026 |
| Northern Trust Corp | 69.0K | 0.22% | -62.35% | Jun 2026 |
| Qube Research & Technologies | 63.8K | 0.20% | 0.00% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 60.7K | 0.19% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 57.2K | 0.18% | 0.00% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 54.0K | 0.17% | +1,603.76% | Jun 2026 |
| Bank of America Corp | 51.7K | 0.16% | -16.84% | Jun 2026 |
Avita Medical Ltd company profile
- Company name
- Avita Medical Ltd
- Ticker
- RCEL.US
- Exchange
- USA Stocks
- Listed since
- Oct 1, 2019
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 226
- Fiscal year end
- December
- Address
- 28159 Avenue Stanford, Valencia, CA, United States, 91355
- Phone
- 661 367 9170
- Website
- avitamedical.com
About Avita Medical Ltd
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.
Avita Medical Ltd management
10- Mr. Cary G. VancePresident, CEO & Executive Director · born 1966
- Mr. David O'TooleChief Financial Officer · born 1959
- Ms. Nicole Linda KelseyChief Legal & Compliance Officer & Corporate Secretary · born 1967
- Dr. Niraj Doshi J.D., P.M.P., Ph.D.Senior Vice President of Global Operations
- Dr. Katie Bush Ph.D.Senior Vice President of Scientific & Medical Affairs
- Mr. Ben AtkinsVice President of Investor Relations & Corporate Communications
- Ms. Debbie GarnerSenior Vice President of Global Marketing & Strategy
- Mr. Rob JonesSenior Vice President of Human Resources
- Mr. Ron LagerquistSenior Vice President of Quality Assurance & Regulatory Affairs
- Ms. Robin VanDenburghSenior Vice President of U.S. Commercial Sales